Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imlifidase for acute severe AQP4-IgG neuromyelitis optica spectrum disorder attacks
NL-OMON60075Phase 2Completed
- Sponsor
- Erasmus MC
- Start
- Aug 2025
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of imlifidase in Neuromyelitis Optica Spectrum Disorder (NMOSD), sponsored by Erasmus MC. Started Aug 2025; status: completed.
02
Drugs
imlifidase
03
Conditions
Neuromyelitis Optica Spectrum Disorder (NMOSD)
Beyond the preview
Go deeper on NL-OMON60075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60075.